Cellphire, Inc. is a biotechnology company spunout of Adlyfe, Inc. in early 2006. The company focus is on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets. Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics. We have been able to stabilize and modify platelets into a product that can be stored well beyond the current limit of 5-7 days. Platelets are often in short supply because of this extremely short shelf life which then causes problems in the treatment of cancer patients and actively bleeding surgical or trauma patients. The fragility of the national supply of platelets is a topic of discussion of several task forces and agencies planning the nation's response to a pandemic such as avian influenza. This and other natural or manmade disasters would interrupt the constant supply of platelets that is a healthcare requirement.